The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants

Premature Birth Clinical Trial

Official title:

The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05490173
• Other study ID #: ncagp4382277
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 5, 2022
• Est. completion date: December 28, 2026

Study information

• Verified date: September 2022
• Source: Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
• Contact: Oleg Ionov, PhD, MD
• Phone: +74954382277
• Email: dr.ionov[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study the safety and efficacy of intranasal administration of exosomes derived from mesenchymal stromal cells on long-term neurodevelopmental outcome in extremely low birth weight infants born at gestational age 25/0-27/6 weeks.

Description:

Surviving extremely low birth weight (ELBW) infants are at risk of severe neurodevelopmental disability. Exosomes or extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) can mediate a variety of different effects, including synaptic plasticity, nutritional metabolic support, nerve regeneration, inflammatory response, anti-stress effect, cellular waste disposal, treating neurological injury, preventing hemorrhagic and ischemic brain lesions, playing an important role in health and neuroprotection in extremely premature newborns during neonatal intensive care. The proposed blinded randomized controlled trial was designed to compare the effect of intranasal administration of exosomes on long-term neurodevelopmental outcome in ELBW infants. ELBW infants will be randomized to receive (group 1) and not receive exosomes (control group). Group 1 - Neonates will receive exosomes (1 dose will be obtained from a daily conditioned culture medium of 120 million MSCs) suspended in 500 µl of phosphate buffer in each nostril at 50 µl with an interval of 2-3 minutes. The therapeutic course will consist of 5 instillations with an interval of 1 days. The primary outcome measure is the incidence of death, the incidence of survival with any of either severe intraventricular hemorrhage (IVH), cystic periventricular leukomalacia (PVL), or brain injury on cranial ultrasound and MRI or major neurodevelopmental impairment determined at 36 months of age corrected for prematurity (where major neurodevelopmental impairment is defined as any of the following: cognitive deficit, cerebral palsy, or severe visual or hearing impairment. Cognitive delay defined as mental developmental index (MDI) score of the Griffiths-II and Bayley Scales of Infant Development (2nd edition) < 85, cerebral palsy, or severe visual or hearing impairment. To investigate this outcomes and the mechanisms by which extracellular vesicles (EVs) might effect we will analyze the biomarkers of perinatal brain injury (S-100, NSE, EPO) and mRNA. Key secondary outcomes are incidences of short term outcomes: individual components of the composite primary outcome, survival with and without major neonatal morbidity including severe retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC). Safety analyses will assess the injures or damages of the nasal mucosa, allergic reaction to EVs and any adverse events after intranasal administration of EVs. The results of this trial may help to improve the quality of life of ELBW infants and reduce long-term health care costs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: December 28, 2026
• Est. primary completion date: May 22, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 3 Days

Eligibility

Inclusion Criteria:

• Premature newborns of gestational age (GA) 25/0-27/6 weeks,

Exclusion Criteria:

• Missing written parental consent
• Damages to the nasal mucosa
• Maxillofacial defects
• Major congenital anomalies (including chromosomal aberrations, cyanotic congenital heart defects, syndromes likely affecting long-term outcome, and major congenital malformations requiring surgical correction during newborn period)
• Infants who died before 48 hours, infants in whom the clinical decision to withhold intensive care was made, infants who were not considered viable
• Infants with edematous hemolytic disease of newborns, non-immune fetal dropsy,
• Multifetal Gestations
• Participation in another study with ongoing use of an unlicensed investigational product from 28 days before study enrollment until the end of the study

Related Conditions & MeSH terms

• Birth Weight
• Brain Ischemia
• Extreme Prematurity
• Hemorrhage
• Hypoxia
• Hypoxia-Ischemia, Brain
• Hypoxia-Ischemia, Cerebral
• Ischemia
• Neurodevelopmental Disorders
• Premature Birth

Intervention

Other:
• Exosomes derived from mesenchymal stromal cells (MSCs)
Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants

Locations

Country	Name	City	State
Russian Federation	Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Country where clinical trial is conducted

Russian Federation, 

References & Publications (3)

Drommelschmidt K, Serdar M, Bendix I, Herz J, Bertling F, Prager S, Keller M, Ludwig AK, Duhan V, Radtke S, de Miroschedji K, Horn PA, van de Looij Y, Giebel B, Felderhoff-Müser U. Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. Brain Behav Immun. 2017 Feb;60:220-232. doi: 10.1016/j.bbi.2016.11.011. Epub 2016 Nov 12. — View Citation

Gamage TKJB, Fraser M. The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury. Front Neurosci. 2021 Sep 24;15:744840. doi: 10.3389/fnins.2021.744840. eColle — View Citation

Ophelders DR, Wolfs TG, Jellema RK, Zwanenburg A, Andriessen P, Delhaas T, Ludwig AK, Radtke S, Peters V, Janssen L, Giebel B, Kramer BW. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl Med. 2016 Jun;5(6):754-63. doi: 10.5966/sctm.2015-0197. Epub 2016 May 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence and rate of dose limiting toxicity	Dose limiting toxicity consists of the following events: Death occurring within 24 hours after intranasal administration of EVs; Hypersensitivity / anaphylactic to EVs defined as any severe systemic inflammatory response syndrome with negative blood culture not consistent with the overall clinical course of the infant occurring within 72 hours after intranasal administration of EVs; Any other serious adverse event not expected in this patient population for which there is no alternative explanation but the administration of EVs, occurring within 1 week of injection.	Up to 1 week following after intranasal administration of EVs
Secondary	Rate of death	Rate of death until discharge or 40 weeks corrected gestational age, whichever comes first	From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)
Secondary	Occurrence of Other Severe Complications of Prematurity	Blood culture-proven sepsis; Patent ductus arteriosus (treated medically or surgically); Necrotizing enterocolitis; Isolated intestinal perforation; Retinopathy of prematurity requiring treatment; Severe intraventricular hemorrhage (= grade 3); Cystic periventricular leukomalacia; Incidence and Severity of BPD, Measured as mild, moderate, or severe	From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)
Secondary	Need for Ventilatory Support	Time to extubation; Duration of mechanical ventilation; Duration of non-invasive positive pressure respiratory support; Duration of supplemental oxygen	From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)
Secondary	Changes in Hemodynamics	Targeted neonatal echocardiography to assess	Time Frame: At enrollment, 48 hours following intranasal administration of EVs, 28 days of life, and 36 weeks corrected gestational age
Secondary	Feasibility: Administration	Successful recruitment and administration of extracellular vesicles to 10 patients in 18 months	Day of life 1-10
Secondary	Feasibility: Recruitment Efficiency	Proportion of potentially eligible patients that are successfully screened; Proportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded)	Day of life 1-10
Secondary	Feasibility: Recruitment Timing	Median time from screening to enrollment; Median time from screening to extracellular vesicles	Day of life 1-10
Secondary	Feasibility: Participant Retainment	Proportion of patients that do not complete administration of extracellular vesicles; Proportion of patients enrolled that do not undergo scheduled follow-up	From enrollment until follow-up at 18-36 months-of-age
Secondary	Griffiths-II and Bayley Scales of Infant Development (2nd edition)	Assessment of cognitive, language, and motor development. Cognitive delay defined as mental developmental index (MDI) score of the Griffiths-II and Bayley Scales of Infant Development (2nd edition) < 85, cerebral palsy, or severe visual or hearing impairment.	18-36 months-of-age
Secondary	Long-term Safety Follow-Up	Participant's overall health will be assessed through a questionnaire administered over the phone, once a year for 3 years	3 years following follow-up visit

External Links

•   Brain Tissue-Derived Extracellular Vesicle Mediated Therapy in the Neonatal Ischemic Brain
•   Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury
•   Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia
•   The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury
•   The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury